Bifidobacterium lactis

Bifidobacterium animalis subsp. lactis

Entire Monograph

Reported Uses

NOTE: see Herb & Supplement Effectiveness Rating Definitions table
allergic rhinitis [Insufficient Evidence]
aphthous ulcer (canker sores) [Insufficient Evidence]
atopic dermatitis (eczema) [Insufficient Evidence]
bipolar disorder [Insufficient Evidence]
cancer [Insufficient Evidence]
candidiasis, oropharyngeal [Insufficient Evidence]
C. difficile infection [Insufficient Evidence]
child development [Insufficient Evidence]
colic [Possibly Effective]
constipation [Possibly Effective]
critical illness (trauma) [Insufficient Evidence]
dental caries [Possibly Ineffective]
dental plaque [Insufficient Evidence]
diabetes [Insufficient Evidence]
diarrhea [Insufficient Evidence]
diarrhea, antibiotic-associated [Insufficient Evidence]
diarrhea, malnourishment-related [Insufficient Evidence]
diarrhea, radiation-related [Insufficient Evidence]
diarrhea, rotaviral [Insufficient Evidence]
familial hypercholesterolemia [Insufficient Evidence]
generalized anxiety disorder [Insufficient Evidence]
gingivitis [Insufficient Evidence]
H. pylori infection [Insufficient Evidence]
hypercholesterolemia [Insufficient Evidence]
IBS [Possibly Effective]
inflammatory bowel disease [Insufficient Evidence]
malnutrition [Insufficient Evidence]
metabolic syndrome [Insufficient Evidence]
nausea/vomiting, pregnancy-induced [Insufficient Evidence]
necrotizing enterocolitis [Insufficient Evidence]
neonatal jaundice [Insufficient Evidence]
metabolic dysfunction-associated steatotic liver disease [Insufficient Evidence]
obesity [Insufficient Evidence]
otitis media [Insufficient Evidence]
periodontitis [Insufficient Evidence]
postop bowel function [Insufficient Evidence]
postpartum depression [Insufficient Evidence]
Prader-Willi syndrome [Insufficient Evidence]
prematurity [Insufficient Evidence]
psoriasis [Insufficient Evidence]
respiratory infections [Possibly Effective]
rheumatoid arthritis [Insufficient Evidence]
ulcerative colitis [Insufficient Evidence]
UTI [Insufficient Evidence]
ventilator-associated pneumonia prevention [Insufficient Evidence]

Reported Doses

Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies with variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely

Special Note

[formulation clarification]
Info: uses and doses represent various probiotic-containing products; other Bifidobacteria species exist, but are not included

Effectiveness Ratings

[see Herb & Supplement Effectiveness Rating Definitions table]

allergic rhinitis, peds patients

[Insufficient Evidence]
Dose: 4 billion CFUs PO qd (B. lactis BB-12 DSM 15954 plus other probiotics); Info: for patients 6 yo and older

aphthous ulcer (canker sores)

[Insufficient Evidence]
Dose: 3 billion CFUs lozenge PO qd (B. lactis plus other probiotics)

atopic dermatitis (eczema) tx

[Insufficient Evidence]
Dose: 30-80 billion CFUs PO qd (B. lactis BB-12); Alt: 1 billion CFUs PO qd (B. lactis CECT8145 plus other probiotics); 10 billion CFUs PO qd (B. lactis UABLA-12 plus other probiotics); Info: for use in peds patients

atopic dermatitis (eczema) prevention

[Insufficient Evidence]
Dose: 2 billion CFUs PO qd (B. lactis plus other probiotics) in infants; Alt: 105 billion CFUs PO qd (B. lactis BB-12 plus other probiotics) starting 36 wk gestation for childhood prevention

bipolar disorder

[Insufficient Evidence]
Dose: 100 million CFUs PO qd (B. lactis BB-12 plus other probiotics)

colic

[Possibly Effective]
Dose: 1 billion CFUs PO qd (B. lactis BB-12)

constipation

[Possibly Effective]
Dose: 5 billion CFUs PO qd (B. lactis LMG P-21384); Alt: 100 million CFUs PO qd (B. lactis Bi-07); 12.5 billion CFUs PO qd (B. lactis DN-173 010); 10 billion CFUs PO qd (B. lactis GCL2505)); 1-10 billion CFUs PO qd (B. lactis BB-12); 1-10 billion CFUs PO qd (B. lactis HN019)

critical illness (trauma)

[Insufficient Evidence]
Dose: 5.5 billion CFUs PO bid (B. lactis BB12 plus other probiotics)

dental plaque

[Insufficient Evidence]
Dose: 100 million CFUs PO qd (B. lactis DN-173010); Alt: 1.82 billion CFUs lozenge PO bid (B. lactis BB-12 plus other probiotics); 4 billion CFUs lozenge PO qd (B. lactis BB-12 plus other probiotics)

diabetes

[Insufficient Evidence]
Dose: 2 billion CFUs PO qd (B. lactis BB-12 plus other probiotics)

diarrhea, antibiotic-associated

[Insufficient Evidence]
Dose: 19.4 billion CFUs PO qd (B. lactis BB-12 plus other probiotics)

diarrhea, radiation-related

[Insufficient Evidence]
Dose 1.75 billion CFUs PO tid (B. lactis BB-12 plus other probiotics)

familial hypercholesterolemia

[Insufficient Evidence]
Dose: 3 billion CFUs PO qd (B. lactis MB 2409 plus other probiotics)

generalized anxiety disorder

[Insufficient Evidence]
Dose: 18 billion CFUs PO qd (B. lactis plus other probiotics); Info: used with sertraline

gingivitis

[Insufficient Evidence]
Dose: 100 million CFUs PO qd (B. lactis DN-173010); Alt: 1 billion CFUs lozenge PO bid (B. lactis HN019 plus other probiotics); 1.84 billion CFUs lozenge PO bid (B. lactis BB-12 plus other probiotics); 4 billion CFUs lozenge PO qd (B. lactis BB-12 plus other probiotics)

H. pylori infection

[Insufficient Evidence]
Dose: 7 billion CFUs PO qd (B. lactis B94); Alt: 5 billion CFUs PO qd (B. lactis plus other probiotics); Info: used with standard tx

IBS, adult patients

[Possibly Effective]
Dose: 10 billion CFUs PO qd (B. lactis UABla-12); Alt: 2.5 billion CFUs PO bid (B. lactis BL040 plus other probiotics)

IBS, peds patients

[Possibly Effective]
Dose: 10 billion CFUs PO qd (B. lactis B19); Info: for patients 4 yo and older

inflammatory bowel disease

[Insufficient Evidence]
Dose: 20 billion CFUs PO bid (B. lactis BB-12 plus other probiotics)

metabolic syndrome

[Insufficient Evidence]
Dose: 27.2 billion CFUs PO qd (B. lactis HN019)

nausea/vomiting, pregnancy-induced

[Insufficient Evidence]
Dose: 20 billion CFUs PO qd (B. lactis Bl-04 plus other probiotics)

neonatal jaundice

[Insufficient Evidence]
Dose: 5 billion CFUs PO bid (B. lactis CP-9)

metabolic dysfunction-associated steatotic liver disease

[Insufficient Evidence]
Dose: 13 billion CFUs PO qd (B. lactis DSMZ32269 plus other probiotics); Info: for use in peds patients

obesity

[Insufficient Evidence]
Dose: 10 billion CFUs PO qd (B. lactis CECT8145); Alt: 10 billion CFUs PO qd (B. lactis 420 plus other probiotics); 50 billion CFUs PO qd (B. lactis plus other probiotics)

periodontitis

[Insufficient Evidence]
Dose: 1 billion CFUs lozenge PO bid (B. lactis HN019)

postop bowel function

[Insufficient Evidence]
Dose: 2 billion CFUs PO qd (B. lactis MH-02)

Prader-Willi syndrome, peds patients

[Insufficient Evidence]
Dose: 10 billion CFUs PO qd (B. lactis BPL1 CECT8145); Alt: 30 billion CFUs PO bid (B. lactis BL-11); Info: for use in peds patients

psoriasis

[Insufficient Evidence]
Dose: 2.6 billion CFUs/day PO divided bid (B. lactis plus other probiotics)

respiratory infections, adult patients

[Possibly Effective]
Dose: 50 billion CFUs PO qd (B. lactis Lab4P plus other probiotics); Alt: 2 billion CFUs PO qd (B. lactis BB-12 plus other probiotics)

respiratory infections, peds patients

[Possibly Effective]
Dose: 141 g (1 million CFUs/g) formula PO qd (B. lactis HN019); Alt: 2-10 billion CFUs PO qd (B. lactis BB-12); 10 billion CFUs PO bid (B. lactis plus other probiotics); 12.5 billion CFUs PO qd (B. lactis CUL34 plus other probiotics); 5 billion CFUs PO qd (B. lactis UABLA-12 plus other probiotics); 20 billion CFUs PO qd (B. lactis probio-M8)

UTI

[Insufficient Evidence]
Dose: 1.75 billion CFUs/kg/dose PO bid (B. lactis plus other probiotics); Info: for use in peds patients

ventilator-associated pneumonia prevention

[Insufficient Evidence]
Dose: 5.5 billion CFUs PO bid (B. lactis BB12 plus other probiotics)